It suggests that type 2 mellitus and AD, in particular sporadic AD (sAD), share common risk factors, and molecular mechanisms, including impairment of insulin/IGF—1 signaling, and thus potentially common therapeutic targets [15]. The gene discussed is IGF1; the disease is Alzheimer disease.